跳至主要内容
临床试验/NCT01790386
NCT01790386已完成不适用

Equivalency Study of the CORA(R) and TEG(R) 5000 Systems

Coramed Technologies LLC4 个研究点 分布在 1 个国家目标入组 465 人开始时间: 2013年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
465
试验地点
4
主要终点
Measurement of differences in TEG and CORA hemostasis parameters per patient

研究概览

简要总结

This study is being performed to obtain data about the CORA system, a new device that is currently being tested and is not yet cleared for sale in the United State by the Food and Drug Administration (FDA). The purpose of the study is to validate the CORA system by comparing the results of this test to that of the standard of care device called the TEG system. Both systems evaluate hemostasis, a highly complex and interactive process involving many protein and cellular elements, especially platelets, occurring in a series of interrelated phases, which results in either normal hemostasis or a tendency toward bleeding or clotting complications.

详细描述

The study protocol specifies testing using multiple reagents which are similar for both the CORA and TEG systems. Tests are run on blood samples taken from patients undergoing cardiovascular surgery and cardiology procedures, at two times throughout the procedure. The tests may be performed at three different pairs of times: Pre-Operation and Post-Protamine, or During Operation (Post-Heparin) and ICU, or Pre-Operation and ICU. Patients are selected at random for determination of which pair of times will be used, as long as the number of patients for each of the three groups is approximately the same. Following the protocol defined in CLSI Standard EP09-A2, equivalence between the two systems will be demonstrated if the conclusions from the Standard Section 7, Interpreting Results and Comparing to Internal Performance Criteria, are found to be acceptable.

The study protocol also specifies the testing of blood samples from normal, health volunteer subjects for the purpose of determining CORA System Reference Ranges for all of the reagents used in the study. Reference ranges will be constructed following the guidelines specified in CLSI Standard C28-A3c.

All blood samples drawn for this study will use venous blood. Whole blood is not used for these studies; only citrated or heparinized samples are used. All samples are repeated twice (run in duplicate tests). Quality Controls are run on both instruments at a frequency specified by the manufacturers. Results obtained from this testing are not used to make treatment decisions.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or over (both groups)
  • Age, gender, ace and disease state documented (both groups)
  • In good health (Reference Ranges group only)

排除标准

  • Subjects/patients under the age of 18 (both groups)
  • On medications affecting hemostasis (Reference Ranges group)
  • Having conditions or undergoing treatments affecting hemostasis (Reference Ranges group)

结局指标

主要结局

Measurement of differences in TEG and CORA hemostasis parameters per patient

时间窗: Parameter differences assessed at completion of patient surgery

次要结局

  • Measurement of test subjects' CORA Hemostasis Parameters(Hemostasis parameters measured at time of test for each subject)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验